Search Result

Results for "

STAT3 dimerization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	STAT (12) Antibiotic (2) Apoptosis (3) Autophagy (1) Bacterial (2) Bcl-2 Family (1) CDK (1) FGFR (1) Interleukin Related (1) JAK (1) MMP (1) NOD-like Receptor (NLR) (1) Reference Standards (2)
By Research Areas:	Cancer (13) Infection (2) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Targets Recommended: STAT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122214

AC-73 Maximum Cited Publications 6 Publications Verification	Autophagy	Cancer
AC-73 is a first specific, orally active inhibitor of cluster of differentiation 147 (CD147), which specifically disrupts CD147 dimerization, thereby mainly suppressing the *CD147*/ERK1/2/STAT3/MMP-2 pathways. AC-73 inhibits the motility and invasion of hepatocellular carcinoma cells . AC-73 is also an anti-proliferative agent and an inducer of autophagy in leukemic cells .

HY-18061

Ochromycinone 3 Publications Verification (Rac)-STA-21	Antibiotic STAT Bacterial	Infection Cancer
Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a *STAT3* inhibitor. Ochromycinone can inhibits *STAT3* DNA binding activity, *STAT3* dimerization. Ochromycinone has anticancer and antimicrobial activity .

HY-103692

STX-0119 2 Publications Verification	STAT	Cancer
STX-0119 is a selective, orally active *STAT3* dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC₅₀ of 74 μM .

HY-W035137

5,15-Diphenylporphyrin 5,15-DPP	STAT	Cancer
5,15-Diphenylporphyrin (5,15-DPP) is an inhibitor of the oncogenic transcription factor *STAT3. 5,15-Diphenylporphyrin specifically binds to the SH2 domain of STAT3, blocking the pTyr-SH2 interaction, thereby inhibiting the dimerization, nuclear translocation and DNA binding activity of STAT3*, and ultimately inhibiting the expression of cancer cell-related genes. 5,15-Diphenylporphyrin can be used in research fields related to the development of anticancer drugs[1][2].

HY-P10114

STAT3-IN-24, cell-permeable PpYLKTK-mts; STAT3 PI	STAT	Cancer
STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a *STAT3* peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .

HY-124843

LLL3 1 Publications Verification CLT-005	STAT Apoptosis	Cancer
LLL3 (CLT-005) is a *STAT3* inhibitor. LLL3 inhibits dimerization and phosphorylation of *STAT3, thereby preventing intraconuclear transfer of STAT3* and inhibits the expression of *STAT3* dependent genes, which encode proteins such as Bcl-xL and cyclin D1. In addition, LLL3 can induce cell growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells via the caspase pathway. LLL3 can be used in the study of *STAT3* persistent activation types of cancer .

HY-100610

S3I-1757	STAT	Cancer
S3I-1757 is a *STAT3* inhibitor. S3I-1757 inhibits the phosphorylation and dimerization of *STAT3. S3I-1757 can be used for the research of STAT3* hyperactive cancers such as melanoma .

HY-18061R

Ochromycinone (Standard) (Rac)-STA-21 (Standard)	Antibiotic Reference Standards STAT Bacterial	Infection Cancer
Ochromycinone (Standard) ((Rac)-STA-21 (Standard)) is the analytical standard of Ochromycinone (HY-18061). This product is intended for research and analytical applications. Ochromycinone is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity.

HY-103692R

STX-0119 (Standard)	Reference Standards STAT	Cancer
STX-0119 (Standard) is the analytical standard of STX-0119 (HY-103692). This product is intended for research and analytical applications. STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC₅₀ of 74 μM .

HY-E70717

FGFR1 V561M Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR1 has been implicated in numerous cancer types including non-small cell lung cancer (NSCLC). FGFR1 is activated upon FGF binding to its extracellular domain, resulting in protein dimerization and transautophosphorylation of the intracellular tyrosine kinase domains. FGFR1 V561M gatekeeper mutation drives Fexagratinib (AZD4547) (HY-13330) resistance through STAT3 Activation and EMT. FGFR1 V561M Recombinant Human Active Protein Kinase is a recombinant FGFR1 V561M protein that can be used to study FGFR1 V561M-related functions .

HY-N17494

Crispene E	STAT Bcl-2 Family CDK	Cancer
Crispene E is a *STAT3* inhibitor with an IC₅₀ of 10.27 μM against STAT3 dimerization. Crispene E exerts specific cytotoxicity against STAT3-dependent MDA-MB-231 breast cancer cells. Crispene E is applicable to research related to breast cancer .

HY-177990

STAT3-IN-52	STAT MMP Apoptosis	Cancer
STAT3-IN-52 (Compound 9) is a selective and orally active signal transducer and activator of transcription 3 (STAT3) inhibitor. STAT3-IN-52 binds to the pY705 site of STAT3 (K_i = 440 nM), blocking the phosphorylation and dimerization of STAT3. STAT3-IN-52 shows strong cytotoxicity against various cancer cells, such as breast cancer MDA-MB-231 (IC₅₀ = 0.7 μM), medulloblastoma UW426, pancreatic cancer BKPC3 cells. STAT3-IN-52 can induce cell apoptosis, inhibit the STAT3 nuclear transport and DNA binding activity and downregulate the expression of the STAT3 target gene MMP9. STAT3-IN-52 can be used for research related to STAT3 abnormal activation in cancer .

HY-183370

JAK2/STAT3-IN-2	JAK STAT Interleukin Related	Inflammation/Immunology
JAK2/STAT3-IN-2 is an orally active *JAK2/STAT3* inhibitor. JAK2/STAT3-IN-2 inhibits the phosphorylation of tyrosine residues in JAK2 and *STAT3, blocks downstream signal transduction, disrupts the dimerization* and nuclear translocation of *STAT3, and suppresses pro-inflammatory transcriptional activity. JAK2/STAT3-IN-2* inhibits the expression of IL-17A and IL-17F, reduces immune cell infiltration, and inhibits the production of NO simultaneously. JAK2/STAT3-IN-2 exerts a protective effect in a mouse model of ulcerative colitis induced by DSS (HY-116282C). JAK2/STAT3-IN-2 can be used for the research of ulcerative colitis .

HY-182380

ODZ10117	STAT NOD-like Receptor (NLR) Apoptosis	Others Neurological Disease Inflammation/Immunology Cancer
ODZ10117 is a *STAT3* and NLRP3 inhibitor with a human STAT3 SH2 domain IC₅₀ of 7.5 μM. ODZ10117 binds to the STAT3 SH2 domain, suppressing tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity. ODZ10117 binds to NLRP3, impairs NEK7 interaction, prevents inflammasome formation, and inhibits caspase-1 and IL-1β cleavage.ODZ10117 reduces MSU (HY-B2130A)-induced IL-1β release, lowers LPS (HY-D1056)-induced sepsis mortality, and exhibits anti-inflammatory effects. ODZ10117 induces apoptosis, suppresses breast cancer cell migration and invasion, reduces tumor growth and lung metastasis, and extends survival in breast cancer models. ODZ10117 can be used for the research of Monosodium urate (HY-B2130A)-induced peritonitis, LPS-induced sepsis, breast cancer, glioblastoma, and Alzheimer's disease .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library	704 compounds
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 704 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

JAK/STAT Compound Library

704 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 704 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P10114

STAT3-IN-24, cell-permeable PpYLKTK-mts; STAT3 PI	STAT	Cancer
STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a *STAT3* peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .

Ochromycinone 3 Publications Verification (Rac)-STA-21	Infection Quinones Monophenols Microorganisms Classification of Application Fields Anthraquinones Phenols Disease Research Fields Source Classification	Antibiotic STAT Bacterial
Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a *STAT3* inhibitor. Ochromycinone can inhibits *STAT3* DNA binding activity, *STAT3* dimerization. Ochromycinone has anticancer and antimicrobial activity .

Ochromycinone (Standard) (Rac)-STA-21 (Standard)	Quinones Monophenols Microorganisms Anthraquinones Phenols Source Classification	Antibiotic Reference Standards STAT Bacterial
Ochromycinone (Standard) ((Rac)-STA-21 (Standard)) is the analytical standard of Ochromycinone (HY-18061). This product is intended for research and analytical applications. Ochromycinone is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity.

Crispene E	Structural Classification Terpenoids Diterpenoids Plants Tinospora crispa (L.) Hook. f. et Thoms Menispermaceae Source Classification	STAT Bcl-2 Family CDK
Crispene E is a *STAT3* inhibitor with an IC₅₀ of 10.27 μM against STAT3 dimerization. Crispene E exerts specific cytotoxicity against STAT3-dependent MDA-MB-231 breast cancer cells. Crispene E is applicable to research related to breast cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks